'Expanding the footprint of African manufacturers in the R21 value chain requires a technology transfer approach that meticulously assesses existing and potential production facilities in Africa with the capacity to manufacture the R21 vaccine in the medium term, including the production of the drug substance.'
#Malaria #Vaccine #PublicHealth
https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0003412
Thiago Carvalho /
npub1xa…czham
2024-08-18 18:25:17
Author Public Key
npub1xakev87fgm9edqu6f5jhszwunekjxl3dpnq4sxvm3nzu2ace8xnqyczhamPublished at
2024-08-18 18:25:17Event JSON
{
"id": "b569b6f064bdcebf26b0946fb525efccbc9d7f1d40d0d3937538f6a9855bb29c",
"pubkey": "376d961fc946cb96839a4d257809dc9e6d237e2d0cc158199b8cc5c5771939a6",
"created_at": 1724005517,
"kind": 1,
"tags": [
[
"t",
"malaria"
],
[
"t",
"vaccine"
],
[
"t",
"publichealth"
],
[
"proxy",
"https://qoto.org/users/cyrilpedia/statuses/112984425609167778",
"activitypub"
]
],
"content": "'Expanding the footprint of African manufacturers in the R21 value chain requires a technology transfer approach that meticulously assesses existing and potential production facilities in Africa with the capacity to manufacture the R21 vaccine in the medium term, including the production of the drug substance.'\n#Malaria #Vaccine #PublicHealth\nhttps://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0003412",
"sig": "6abc716b9ea1c23d57369112ca3d6ec61ede33cdcf18829c095f383f50d6d3009c19afca91b76bce737528e0b13431b98fb2a817fbd5b5f4127362dac20e0747"
}